Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s stock price traded up 6.6% during trading on Thursday . The company traded as high as $14.17 and last traded at $14.19. 335,823 shares were traded during mid-day trading, a decline of 62% from the average session volume of 882,733 shares. The stock had previously closed at $13.31.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright reiterated a "buy" rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, June 17th. Guggenheim set a $48.00 target price on Mineralys Therapeutics and gave the stock a "buy" rating in a report on Wednesday, May 14th. Finally, Jefferies Financial Group initiated coverage on Mineralys Therapeutics in a report on Tuesday, June 10th. They issued a "hold" rating and a $15.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $32.25.
View Our Latest Stock Analysis on MLYS
Mineralys Therapeutics Stock Performance
The firm has a market capitalization of $886.45 million, a PE ratio of -3.65 and a beta of -0.30. The company has a fifty day simple moving average of $14.69 and a two-hundred day simple moving average of $13.19.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.23. On average, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.
Insider Activity at Mineralys Therapeutics
In other news, CEO Jon Congleton sold 15,884 shares of the stock in a transaction dated Friday, July 11th. The stock was sold at an average price of $14.51, for a total value of $230,476.84. Following the transaction, the chief executive officer directly owned 846,405 shares of the company's stock, valued at approximately $12,281,336.55. This represents a 1.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Scott Levy sold 10,758 shares of the stock in a transaction dated Friday, July 11th. The shares were sold at an average price of $14.45, for a total value of $155,453.10. Following the completion of the transaction, the chief financial officer directly owned 206,612 shares in the company, valued at $2,985,543.40. This represents a 4.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,374 shares of company stock valued at $725,546 in the last ninety days. Corporate insiders own 33.24% of the company's stock.
Institutional Trading of Mineralys Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its position in Mineralys Therapeutics by 43.0% during the fourth quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock worth $1,127,000 after purchasing an additional 27,531 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $202,000. GAMMA Investing LLC lifted its position in Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after buying an additional 8,738 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Mineralys Therapeutics during the fourth quarter worth approximately $48,000. Finally, JPMorgan Chase & Co. lifted its position in Mineralys Therapeutics by 2,251.5% during the fourth quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company's stock worth $6,199,000 after buying an additional 482,174 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
See Also
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access